Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16051113 | 0.77 | GRM5 (0.48) | GRM5USP2SMN1; SMN2ESR2GPR119 | |
| SCHEMBL513293 | 0.77 | GRM5 (0.46) | GRM5USP2SMN1; SMN2ESR2GPR119 | |
| Oxalic Acid SCHEMBL8009465 | 0.76 | CHRNB2 (0.43) | CHRNB2CHRNA3 | |
| SCHEMBL7994340 | 0.74 | CHRNB2 (0.49) | CHRNB2CHRNA3 | |
| SCHEMBL512844 | 0.74 | GRM5 (0.44) | GRM5USP2SMN1; SMN2ESR2GPR119 | |
| SCHEMBL18280035 | 0.73 | GRM5 (0.43) | GRM5USP2SMN1; SMN2ESR2GPR119 | |
| SCHEMBL513725 | 0.73 | MMP13 (0.48) | GRM5USP2SMN1; SMN2ESR2GPR119 | |
| SCHEMBL31247165 | 0.72 | KDM4E (0.52) | GPR119 | |
| SCHEMBL31227423 | 0.72 | GRM1 (0.48) | GRM5GPR119 | |
| SCHEMBL16113568 | 0.72 | GRM5 (0.43) | GRM5USP2SMN1; SMN2ESR2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477981-A1 | HETEROCYCLIC MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2012-07-25 | — | — | EP | disclosed |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | GRM5 2/4885USP2 3153/4885SMN1; SMN2 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.